Results of barbiturate antiepileptic drug discontinuation on antipsychotic medication dose in individuals with intellectual disability

Journal of Intellectual Disability Research

Volumn 44, Issue 2, 2000, Pages 155-163

  Hanzel, T E ^a   Bauernfeind, J D ^b   Kalachnik, John E ^c,e   Harder, S R ^d  

^a Hanzel Consulting ^*  (Czech Republic)

^b E Minnesota Comm Support Services   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d St Croix River Education District   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drugs; Antipsychotic drugs; Behavioural side effects; Phenobarbital

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHLORPROTHIXENE; NEUROLEPTIC AGENT; PHENOBARBITAL; PHENYTOIN; THIORIDAZINE; VALPROIC ACID;

ADULT; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; TONIC CLONIC SEIZURE;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME;

EID: 0034082499     PISSN: 09642633     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2788.2000.00273.x     Document Type: Article

References (36)

1. Aman M. G., Sarphare G. & Burrow W. H. (1995) Psychotropic drugs in group homes: prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation 99, 500-9.
2. American Academy of Pediatrics Committee on Drugs (AAPCD) (1985) Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 76, 644-7.
3. American Psychiatric Association (APA) (1995) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington, DC.
4. American Psychiatric Association (APA) (1992) Tardive Dyskinesia. A Task Force Report of the American Psychiatric Association. American Psychiatric Press, Washington, DC.
5. Baumeister A. A., Sevin J. A. & King B. H. (1998) Neuroleptics. In: Psychotropic Medication and Developmental Disabilities: The International Consensus Handbook (eds S. Reiss & M. G. Aman), pp. 133-50. Ohio State University Nisonger Center, Columbus, OH.
6. Beardsley R. S., Freeman J. M. & Appel F. A. (1983) Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 24, 330-5.
7. Bowman Gray School of Medicine of Wake Forrest University (BGSMWFU) (1991) Epilepsy Management in the Multiple Handicapped. K&S Communications, South Norwalk, CT.
8. Camfield P. R., Camfield C. S., Smith E. C. & Tibbles J. A. R. (1985) Newly treated childhood epilepsy: a prospective study of recurrence and side effects. Neurology 35, 722-5.
9. Choonara I. A. & Rane A. (1990) Therapeutic drug monitoring of anticonvulsants. State of the art. Clinical Pharmacokinetics 18, 318-28.
10. Coulter D. L. (1988a) Withdrawal of barbiturate anticonvulsant drugs: prospective controlled study. American Journal on Mental Retardation 93, 320-7.
11. Coulter D. L. (1988b) Withdrawal of sedative anticonvulsant drugs from mentally retarded persons: development of guidelines. Journal of Epilepsy 1, 67-70.
12. Cramer J. A. & Mattson R. H. (1995) Phenobarbital toxicity. In: Antiepileptic Drugs, 4th edn (eds R. H. Levy, R. H. Mattson & B. S. Meldrum), pp. 409-20. Raven, New York, NY.
13. Espie C. A., Gillies J. B. & Montgomery J. M. (1990) Antiepileptic polypharmacy, psychosocial behaviour and locus of control orientation among mentally handicapped adults living in the community. Journal of Mental Deficiency Research 34, 351-60.
14. Ferrari M., Barabas G. & Matthews W. S. (1983) Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. American Journal of Psychiatry 140, 112-13.
15. Facts and Comparisons (1995) Facts and Comparisons, St Louis., MO.
16. Fischbacher E. (1982) Effect of reduction of anticonvulsants on well-being. British Medical Journal 285, 423-4.
17. Gadow K. D. & Poling A. G. (1988) Pharmacotherapy and Mental Retardation. College Hill, Boston, MA.
18. Gay P. E. (1984) Effects of antiepileptic drugs and seizure type on operant responding in mentally retarded persons. Epilepsia 25, 377-86.
19. Gualtieri C. T., Quade D., Hicks R. F., Mayo J. P. & Schroeder S. R. (1984) Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. American Journal of Psychiatry 141, 20-3.
20. Hanzel T. E., Kalachnik J. E. & Harder S. R. (1992) A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. Research in Developmental Disabilities 13, 381-92.
21. Herranz J. L., Armijo J. A. & Arteaga R. (1988) Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy with children. Epilepsia 29, 794-804.
22. Hill B. K., Balow E. A. & Bruinicks R. M. (1985) A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacoiogy Bulletin 21, 279-84.
23. Kalachnik J. E., Hanzel T. E., Harder S. R., Bauernfeind J. D. & Engstrom E. A. (1995) Differential diagnosis of antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Mental Retardation 33, 374-82.
24. Kutt H. (1995) Phenobarbital. Interactions with other drugs. In: Antiepileptic Drugs, 4th edn (eds R. H. Levy, R. H. Mattson & B. S. Meldrum), pp. 389-99. Raven, New York, NY.
25. Linnoila M., Viukari M., Vaisanen K. & Auvinen J. (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry 137, 819-21.
26. Mayhew L. A., Hanzel T. E., Ferron F. R., Kalachnik J. E. & Harder S. R. (1992) Phenobarbital exacerbation of self-injurious behavior. Journal of Nervous and Mental Disease 180, 732-3.
27. McGowan M., Neville B. G. R. & Reynolds E. H. (1983) Comparative monotherapy trial in children with epilepsy. British Journal of Clinical Practice 27 (Suppl.), 115-18.
28. Morgenstern H. & Glazer W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Archives of General Psychiatry 50, 723-33.
29. Pary R. (1993) Mental retardation, mental illness, and seizure diagnosis. American Journal on Mental Retardation 98 (Suppl.), 41-6.
30. Poindexter A. R. & Kolstoe P. D. (1992) Effects of barbiturate withdrawal on behavior. Results from a barbiturate discontinuation program. Habilitative Mental Healthcare Newsletter 11, 63-70.
31. Rivinus T. M. (1982) Psychiatric effects of the anticonvulsant regimens. Journal of Clinical Psychopharmacoiogy 2, 165-92.
32. Singh H., Levinson F., Simpson G. M., Sing Lo E. E. & Friedman E. (1990) Acute dystonia during fixed-dose neuroleptic treatment. Journal of Clinical Psychopharmacology 10, 389-95.
33. Singh B. K. & Towle P. O. (1993) Antiepileptic drug status in adult outpatients with mental retardation. American Journal on Mental Retardation 98 (Suppl.), 41-6.
34. Stores G. (1975) Behavioral effects of anti-epileptic drugs. Developmental Medicine and Child Neurology 17, 647-58.
35. Van Putten T., May P. R. A. & Marder S. R. (1984) Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 41, 1036-9.
36. Wolf S. M. & Forsythe A. (1978) Behavior disturbance, phenobarbital, and febrile seizures. Pediatrics 61, 728-31.